Status:
COMPLETED
Registry of CytoSorb Therapy in COVID-19 ICU Patients
Lead Sponsor:
CytoSorbents, Inc
Collaborating Sponsors:
CytoSorbents Europe GmbH
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
The CTC Registry collects patient-level clinical data on CytoSorb hemoadsorption provided to COVID-19 ICU patients via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorpore...
Eligibility Criteria
Inclusion
- Confirmed COVID-19
- Provision of CytoSorb therapy per Instructions for Use (IFU) of the CytoSorb device.
Exclusion
- CytoSorb therapy for diseases other than COVID-19
- Survival unlikely within 24 hours (for prospectively enrolled patients)
Key Trial Info
Start Date :
August 28 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 20 2022
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT04391920
Start Date
August 28 2020
End Date
January 20 2022
Last Update
February 9 2024
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Center of Aurora
Aurora, Colorado, United States, 80012
2
University of Chicago Medicine
Chicago, Illinois, United States, 60637
3
Franciscan Health Indianapolis
Indianapolis, Indiana, United States, 46237
4
Baptist Memorial Hospital
Southaven, Mississippi, United States, 38671